Option Care Health price target lowered to $30 from $31 at JMP Securities

JMP Securities lowered the firm’s price target on Option Care Health (OPCH) to $30 from $31 and keeps an Outperform rating on the shares. JMP expects the impact of ustekinumab biosimilars to serve as a one-time headwind to profit growth in 2025, but sees other potential growth tailwinds in acute share gains prompted by a large competitor’s exit from the market in late 2024, the continued ramp of recent rare disease therapeutic launches, potential improvements in acute margins in 2025 following various supply disruptions in 2024, and cost efficiencies associated with the resolution of the Change Healthcare cyberattack, the analyst tells investors in a research note. The firm’s recent channel checks lead it to believe the company remains active in its pursuit of specialty and infusion assets that are close to its core.